The relationship between tamoxifen, estrogen, and depressive symptoms

Breast Journal

Volumn 5, Issue 6, 1999, Pages 375-382

  Thompson, Diane S ^a,b,c,d,f   Spanier, Cynthia A ^c   Vogel, Victor G ^a,b,e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f NONE   (United States)

Author keywords

Breast cancer; Depression; Estrogen; Tamoxifen

Indexed keywords

ESTROGEN; FLUOXETINE; MIANSERIN; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN;

ANXIETY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DEPRESSION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NEUROPROTECTION; PSYCHOTHERAPY; QUALITY OF LIFE; SEDATION; SYMPTOMATOLOGY; VERTIGO;

EID: 0032760838     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1999.98085.x     Document Type: Article

References (73)

1. Vogel VG. Tamoxifen for the prevention of breast cancer. In: DeVita VT Jr, Helman S, Rosenberg SA, eds. Important advances in oncology - 1995. Philadelphia: J.B. Lippincott, 1995: 187-200.
2. Love RR. Tamoxifen therapy in early breast cancer: biology, efficacy and side effects. J Clin Oncol 1989;7:803-15.
3. Wiseman H, Lewis D. The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate anti-carcinogenid/carcinogenic actions. Carcinogenesis 1996;17:1357-60.
4. Nayfield SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. Lancet 1991;83: 1450-59.
5. Feting DL. Depression in patients with breast cancer: prevalence, diagnosis, and treatment. Breast J 1997;3:292-302.
6. McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer: diagnosis, biology, and treatment. Arch Gen Psychiatry 1995;52:89-99.
7. Moyer A, Salovery P. Psychosocial sequelae of breast cancer and its treatment. Behav Med 1996;6:110-25.
8. Forsen A. Psychological aspects of breast cancer. Psychiatr Fenn 1990;121:189-200.
9. van Heeringen C, Van Moffaert M, de Cuypere G. Depression after surgery for breast cancer: comparison of mastectomy and lumpectomy. Psychother Psychosom 1989;51:175-79.
10. Hughson A, Cooper A, McArdle C, et al. Psychological impact of adjuvant chemotherapy in the first two years after mastectomy. Br Med J 1986;293:1268-71.
11. Ward S, Viergutz G, Tormey D, et al. Patients' reactions to completion of adjuvant breast cancer therapy. Nurs Res 1992;41:362-66.
12. McKinlay JB, McKinlay SM, Brambilla D. The relative contributions of endocrine changes and social circumstances to depression in mid-aged women. J Health Soc Behav 1987;28: 345-63.
13. Bines J, Oleske MD, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29.
14. Halbreich U. Role of estrogen in postmenopausal depression. Neurology 1997;48:S16-S20.
15. Biegon A, McEwen B. Modulation by estradiol of serotonin receptors in the brain. J Neurosci 1982;2:199-205.
16. Mueck AO, Seeger H, Kasspohl-Butz S, et al. Influence of norethisterone acetate and estradiol on the serotonin metabolism of post menopausal women. Horm Metab Res 1997;29:80-83.
17. Fink G, Sumner BE, Rosie R, et al. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 1996;16:325-44.
18. Schneider MA, Brotherton PL, Hailes J. The effects of exogenous oestrogens on depression in menopausal women. Med J Aust 1977;2:162-63.
19. Limouzin-Lamothe M, Mairon N, Joyce CR, et al. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170:618-24.
20. Peck P. Estrogen aids recall in Alzheimer's women. Clin Psychiatry News 1998;26:5.
21. Gregoine AJ, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996;347:930-33.
22. Sichel DA, Cohen LS, Robertson LM, et al. Prophylactic estrogen in recurrent postpartum affective disorder. Soc Biol Psychiatry 1995;38:814-18.
23. Biegon A, Brewster M, Degani H, et al. A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. Cancer Res 1996;56:4328-31.
24. Wade GN, Blaustein JD, Gray JM, et al. ICI, 182,780: a pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain. Am J Physiology 1993;265: 1392-98.
25. Lee YS, Wurster RD. Bepridil enhances in vitro antitumor activity of antiestrogens in human brain tumor cells. Cancer Lett 1996;110:243-48.
26. Ducharme J, Fried K, Shenouda G, et al. Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. Br J Clin Pharmacol 1997;43:198.
27. Vliagoftis H, Dimitriadon V, Boucher W, et al. Estrodiol augments while tamoxifen inhibits rat mast cell secretion. Int Arch Allergy Immunol 1992;98:398-409.
28. Rabinowicz AL, Hinton DR, Dyck P, et al. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 1995;36:513-15.
29. Lanius RA, Pasqualotto BA, Shaw CA. A novel mechanism of AMPA receptor regulation: ionically triggered kinases and phosphates. Neuroreport 1993;4:795-98.
30. Love RRL, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-47.
31. Kessler RC, McGonagle KA, Zhao S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
32. Culbertson FM. Depression and gender: an international review. Am Psychol 1997;52:25-31.
33. Nolen-Hoeksema S. Sex differences in depression. Stanford, CA: Stanford University Press, 1990.
34. Cathacart CK, Jones SE, Pumroy CS, et al. Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 1993;27:277-81.
35. Shariff S, Cumming CE, Lees A, et al. Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist: an expected on unexpected effect? Ann N Y Acad Sci 1995;761:365-68.
36. Moredo Anelli T, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994;74:74-77.
37. Pluss JL, Dibella NJ. Reversible central nervous system dysfunction due to tamoxifen in a patient with breast cancer. Ann Intern Med 1984;101:652.
38. Ducharme J, Fried K, Shenouda G, et al. Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. Br J Clin Pharmacol 1997;43:189-93.
39. van Dam F, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-18.
40. Hyghson A, Cooper AF, McArdle CS, et al. Psychological impact of adjuvant chemotherapy in the first two years after mastectomy. Br Med J 1986;293:1268-71.
41. Forester B, Kornfeld DS, Fleiss JL, et al. Group psychotherapy during radiotherapy: effects on emotional and physical distress. Am J Psychiatry 1993;150:1700-1706.
42. Taylor SE, Heggeson VS, Reed GM, et al. Self-generated feeling of control and adjustment to physical illness. J Soc Issues 1991;4:91-109.
43. Anderson BL. Psychological interventions for cancer patients to enhance the quality of life. J Consult Clin Psychol 1992;60:552-68.
44. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
45. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;3:56-62.
46. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988; 45:742-47.
47. Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI. A step in the validation of a new self report scale. Br J Psychiatry 1976;128:280-89.
48. Robins LN, Helzer JE, Croughan J, et al. National Institute of Mental Health diagnostic interview schedule: its history, characteristics, and validity. Arch Gen Psychiatry 1981;38: 381-89.
49. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;26:57-63.
50. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured clinical interview for DSM-IV axis I disorders (SCID-I, version 2.0). New York: New York State Psychiatric Institute, 1996.
51. Tarrier N, Maguire P, Kincey J. Locus of control and cognitive behaviour therapy with mastectomy patients: a pilot study. Br J Med Psychol 1983;56:265-70.
52. Van Heeringenn K, Zivkov M. Pharmacological treatment of depression in cancer patients: a placebo-controlled study of mianserin. Br J Psychiatry 1996;169:440-43.
53. Razavi D, Allilaire JF, Smith M, et al. The effects of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 1996;94:205-10.
54. Fawzy FI, Fawzy NW, Arndt LA, et al. Critical review of psychosocial interventions in cancer care. Arch Gen Psychiatry 1995;52:100-13.
55. Speigel D, Bloom JR, Kraemer HC, et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Arch Gen Psychiatry 1989;38:527-33.
56. Fawzy FI, Fawzy NW, Hyun NW, et al. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993;50:681-89.
57. Fisher B, Constantino JP, Wickerham DL, Kavanah M, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
58. Lambert MJ, Hatch DR, Kingston MD. Zung, Beck and Hamilton rating scales as measures of treatment outcome: a metaanalytic comparison. J Consult Clin Psychol 1986;5:54-59.
59. Radloff L. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Measure 1977;1:385-401.
60. Thase ME, Carpenter L, Kupfer DJ, et al. Atypical depression: diagnostic and pharmacological controversies. Psychopharmacol Bull 1991;27:17-22.
61. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression III. Efficacy of monoamine oxidase inhibitors. J Clin Psychiatr 1992;53:5-11.
62. Herman C. International experiences with the Hospital Anxiety and Depression Scale - a review of validation data and clinical results. J Psychosom Res 1997;42:17-41.
63. Hopwood P, Howell A, Maguire P. Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. Br J Cancer 1991;6:349-52.
64. Hopwood P, Howell A, Maguire P. Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer 1991;64: 353-56.
65. Pinder KL, Ramirez AJ, Black ME, et al. Psychiatric disorders in patients with advanced breast cancer: prevalence and associated factors. Eur J Cancer 1993;29:524-27.
66. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
67. Hall A, Ahern R, Fallowfield L. Are we using appropriate self report questionnaires for detecting anxiety and depression in women with early breast cancer? Eur J Cancer 1999;35: 78-85.
68. Segal DL, Hersen M, Van Hasselt VB. Reliability of the structured clinical interview for DSM-III-R: an evaluative review. Comp Psychiatry 1994;35:316-27.
69. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
70. Zung WWK. Evaluating treatment methods for depressive disorders. Am J Psychiatry 1969;126:116-21.
71. Zung WWK, Wonnacott TH. Treatment prediction in depression using a self-rating scale. Biol Psychiatry 1970;2: 321-29.
72. Zung WWK. A cross-cultural survey of depressive symptomatology in normal adults. J Crosscult Psychol 1972;3: 177-83.
73. Zung WWK. From art to science: the diagnosis and treatment of depression. Arch Gen Psychiatry 1973;29:328-37.